Marker Therapeutics (MRKR) Divestments (2022 - 2023)

Marker Therapeutics (MRKR) posted quarterly Divestments of $18.8 million for Q2 2023, up 16774.42% quarter-over-quarter from -$112608.0 in Q1 2023.

Marker Therapeutics (MRKR) Divestments (2022 - 2023) Analysis & Trends

Marker Therapeutics (MRKR) has reported Divestments for 2 consecutive years, with $18.8 million the latest figure, recorded in Q2 2023.

In Q2 2023, Divestments changed N/A year-over-year to $18.8 million; the TTM figure through Dec 2023 stood at $18.7 million (changed N/A YoY), while the FY2023 annual figure was $18.7 million, up 477.42% from the prior year.
Divestments grew to $18.8 million in Q2 2023 per MRKR's latest filing, from -$112608.0 in the prior quarter.
Across five years, Divestments topped out at $18.8 million in Q2 2023 and bottomed at -$127342.0 in Q4 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Divestments (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	-
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	-
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	-
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	-
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	-
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	-
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	-13.21 Mn
10	Marker Therapeutics	27.04 Mn	15.11 Mn	-	-

Download Data